Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis
Viruses · 2023
DOI: 10.3390/v15102026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Steven Flamm und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Digestive Diseases and Nutrition, Rush University Medical Center, Chicago, IL 60612, USA. Hauptthemen laut MEDLINE: Hepatitis C, Hepatitis C, Chronic. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Gilead Sciences, Inc..
Abstract (Originalsprache)
A fixed-dose combination of sofosbuvir/velpatasvir (SOF/VEL) plus weight-based ribavirin (RBV) for 12 weeks is recommended for the treatment of patients with hepatitis C virus (HCV)-associated decompensated cirrhosis. However, large global studies, while confirming the effectiveness of SOF/VEL in a broad range of patients, often exclude these patients. This Phase 2, single-arm, open-label study in adult patients with HCV-associated decompensated cirrhosis in France and the USA aimed to provide further data on the safety and efficacy of SOF/VEL plus RBV for 12 weeks in this population. Patients were treated with a fixed-dose combination of SOF 400 mg/VEL 100 mg plus weight-based RBV once daily for 12 weeks. The inclusion criteria were chronic HCV infection (≥6 months), quantifiable HCV RNA at screening, Child–Turcotte–Pugh class B or C cirrhosis, and liver imaging within 6 months of Day 1 to exclude hepatocellular carcinoma. Among 32 patients who initiated treatment, 78.1% achieved sustained virologic response 12 weeks after the end of treatment (SVR12). Failure to achieve SVR12 was due to non-virologic reasons (investigator discretion, n = 1; death, n = 6). All 25 patients in the per-protocol population achieved SVR12 and all but one achieved sustained virologic response 24 weeks after the end of treatment. Adverse events (AEs) were as expected for a patient population with advanced liver disease. All Grade 3–4 and serious AEs and deaths were deemed unrelated to treatment. In patients with HCV-associated decompensated cirrhosis, SOF/VEL plus RBV achieved high SVR12 rates and was generally well tolerated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Division of Digestive Diseases and Nutrition, Rush University Medical Center, Chicago, IL 60612, USA.
- Texas Liver Institute, University of Texas Health San Antonio, San Antonio, TX 78215, USA.
- Southern Therapy and Advanced Research LLC, Jackson, MS 39216, USA.
- Intermountain Medical Center, Murray, UT 84107, USA.
- Division of Gastroenterology and Hepatology, University of Washington, Seattle, WA 98101, USA.
- Department of Medicine, Division of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, PA 19104, USA.
ORCID-Profile: Renee-Claude Mercier
Förderung
- NCI NIH HHS
- Gilead Sciences, Inc.
Zitieren
APA
Flamm, S., Lawitz, E., Borg, B., Charlton, M., Landis, C., Reddy, K. R., Shiffman, M., Alsina, A., Chang, C., Ravendhran, N., Hernandez, C., Hézode, C., Scherbakovsky, S., Mercier, R. C., & Samuel, D. (2023). Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis. Viruses. https://doi.org/10.3390/v15102026
Vancouver
Flamm S, Lawitz E, Borg B, Charlton M, Landis C, Reddy KR, et al. Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis. Viruses. 2023. doi:10.3390/v15102026
BibTeX
@article{Flamm2023,
author = {Flamm, Steven and Lawitz, Eric and Borg, Brian and Charlton, Michael and Landis, Charles and Reddy, K Rajender and Shiffman, Mitchell and Alsina, Angel and Chang, Charissa and Ravendhran, Natarajan and Hernandez, Candido and Hézode, Christophe and Scherbakovsky, Stacey and Mercier, Renee-Claude and Samuel, Didier},
title = {Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis},
journal = {Viruses},
year = {2023},
doi = {10.3390/v15102026}
}
EUVIMED